drugset
Drugs / Lamivudine/Zidovudine
last change Oct 2007 re-read 2 minutes ago

Lamivudine/Zidovudine

also known as Combivir
Developed for
HIV infectious disease
Investigated by
Glaxo Wellcome

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT00002217 — HIV infectious disease Glaxo Wellcome Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2007-10-29 Gilead Sciences Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients gilead.com ↗
2007-07-23 Gilead Sciences 144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney gilead.com ↗
2006-12-15 Gilead Sciences 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com ↗
2006-08-14 Gilead Sciences 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com ↗
2006-01-18 Gilead Sciences Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Lamivudine/Zidovudine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002217 ↗
Known as Combivir “In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.” NCT00002217 ↗